SW-BIC-213
/ Stemirna Therap
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 04, 2024
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos).
(PubMed, EClinicalMedicine)
- P3 | "A heterologous booster with the COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and proves highly immunogenic and efficacious in preventing symptomatic COVID-19 in individuals who have previously received two doses of inactivated vaccine. Shanghai Strategic Emerging Industries Development Special Fund, Biomedical Technology Support Special Project of Shanghai "Science and Technology Innovation Action Plan", Shanghai Municipal Science and Technology Commission."
Clinical • Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 20, 2023
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
(clinicaltrials.gov)
- P2/3 | N=800 | Not yet recruiting | Sponsor: Stemirna Therapeutics
New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 27, 2023
Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial.
(PubMed, EBioMedicine)
- "SW-BIC-213, a core-shell structured lipopolyplex (LPP) based mRNA vaccine, was safe, tolerable, and immunogenic as a heterologous booster in healthy Chinese adults."
Journal • P1 data • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases
April 12, 2023
New Generation mRNA Booster Vaccine Against Emerging VOCs
(clinicaltrials.gov)
- P3 | N=2000 | Recruiting | Sponsor: Stemirna Therapeutics | Trial primary completion date: Dec 2022 ➔ May 2023
Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
January 17, 2023
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
(clinicaltrials.gov)
- P3 | N=600 | Active, not recruiting | Sponsor: Stemirna Therapeutics
New P3 trial • Infectious Disease • Novel Coronavirus Disease
October 14, 2022
New Generation mRNA Booster Vaccine Against Emerging VOCs
(clinicaltrials.gov)
- P3 | N=2000 | Recruiting | Sponsor: Stemirna Therapeutics
New P3 trial • Infectious Disease • Novel Coronavirus Disease
1 to 6
Of
6
Go to page
1